A US Food and Drug Administration advisory committee on 16 November took a strongly favorable view of Ardelyx Inc.’s Xphozah (tenapanor) for reducing serum phosphorous levels in dialysis patients, waving aside agency reviewers’ concerns about the magnitude of treatment effect and tolerability.
The Cardiovascular and Renal Drugs Advisory Committee overwhelming voted that the phosphate absorption inhibitor’s benefits outweigh its risks in controlling...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?